Written by The Influenza Diagnostics Market is gaining momentum as governments, hospitals, and diagnostic providers strengthen their ability to monitor seasonal influenza and emerging respiratory threats. Increasing demand for timely testing is encouraging investment in both centralized laboratory systems and decentralized diagnostic solutions. The industry is expected to grow at a 6.15% CAGR between 2026 and 2035.
Molecular testing is becoming increasingly important because of its ability to deliver sensitive and rapid results. RT-PCR continues to anchor the molecular segment, while CRISPR-based assays are emerging as a high-growth technology. Advances in automated laboratory systems and AI-supported quality control are also helping laboratories improve throughput and operational efficiency.
Rapid influenza tests accounted for 44.0% of market share in 2025, making them the leading test category by volume. CRISPR-based and other molecular tests are projected to grow more quickly, while point-of-care testing is becoming an important distribution and testing channel. These developments are broadening access to influenza diagnostics beyond traditional laboratories.
North America held the largest regional share at 40.0% in 2025, while Asia-Pacific is expected to expand at an 8.40% CAGR. Public-health laboratory investments, increasing molecular testing capacity, multiplex respiratory panels, and home-based testing are expected to support long-term growth. The integration of human and veterinary influenza surveillance may also create additional opportunities.
Understand industry shifts with well-researched analysis:
South Korea Immunoassay Market Growth
China Leigh Syndrome Treatment Market Demand